20 Future Belgian HealthTech and MedTech Leaders

Nelson Advisors
9 hours ago
12 min read

The Ascendance of the Belgian HealthTech and MedTech Ecosystem: Analysis of 20 Future Leaders

The Belgian healthcare innovation landscape has undergone a tectonic shift over the last decade, evolving from a traditional pharmaceutical stronghold into a globally recognised "Health and Biotech Valley". This maturation is not merely a product of historical legacy but the result of a deliberate, multi-layered strategy involving institutional catalysts, regional specialisation and a robust venture capital framework that prioritises deeptech inter-disciplinarity

The convergence of biotechnology, medical devices (MedTech) and digital health solutions has created an environment where the boundaries between hardware, software and biology are increasingly porous.

Institutional Foundations and the Spin-Off Paradigm

The engine of Belgian innovation is rooted in its research institutions, most notably the Flanders Institute for Biotechnology (VIB) and imec. The VIB has established a formidable track record, launching 39 spin-offs and securing over €1.8 Billion in venture capital. This institutional success is measured not only in capital but in scientific impact; for every Euro of core funding from the Flemish government, the VIB generates approximately €12 for the regional economy.

The institute’s holistic approach extends beyond basic research to include infrastructure development, such as the bio-incubators in Ghent, Leuven and Brussels, which provide the essential wet-lab space and mentorship required for early-stage scaling.

Simultaneously, imec has leveraged its status as a world leader in nanoelectronics to address the "memory wall" and data processing bottlenecks inherent in modern medical AI. Through its venturing arm, imec.xpand and its accelerator program, imec.istart, the centre has become a primary architect of the Belgian MedTech sector, fostering startups that utilise semiconductor precision for biological monitoring and therapeutic intervention. The integration of these two giants, VIB’s biological mastery and imec’s electronic precision, defines the unique value proposition of the Belgian ecosystem.

Institutional Impact Metrics (2023-2024)	VIB (Biotech)	imec (MedTech/Digital)
Spin-offs Launched (Total)	39	Over 30 (Active in Health)
Venture Capital Secured	€1.8 Billion	€941 Million (Annual Revenue)
Gross Value Added (Annual)	€1 Billion	N/A (Global Entity)
Employment Supported	11,000 Jobs	>5,000 Employees

Regional Specialisation and the Merger of Clusters

Belgium’s geographic compacting facilitates a level of collaboration that is rare in larger jurisdictions. Wallonia has carved out a dominant position in Advanced Therapy Medicinal Products (ATMPs) and nuclear medicine. The BioWin cluster in Wallonia represents over 90% of the region’s health-biotechnology players, focusing on a "Health and Biotech Valley" vision that integrates vaccines, biomedicines, and cellular therapies.

This specialisation is supported by the BioPark in Charleroi and the LégiaPark in Liège, which offer specialized infrastructure for radiopharmaceutical production and GMP cell-therapy operations.

In Flanders, the recent merger of the industry organization flanders.bio and the spearhead cluster MEDVIA signals a strategic move toward a unified representation of the sector.

By bringing together "red, green, and white" biotech with healthtech developers, hospitals, and academic institutes, the new organisation aims to address global challenges with a single, more efficient voice. This merger is expected to streamline the "Say Yes to the US" program, which facilitates the entry of Flemish companies into the North American market, recognising that international expansion is critical for the survival of high-growth MedTech firms.

Analysis of the 20 Future Belgian Leaders in HealthTech and MedTech

The following entities represent the vanguard of Belgian medical innovation, characterised by deep technical moats, significant capital backing, and leadership teams with proven expertise in navigating the complex regulatory landscapes of the EMA and FDA.

1. AgomAb Therapeutics: Mastering the Fibrotic Microenvironment

AgomAb Therapeutics, situated in Ghent, has emerged as a powerhouse in the treatment of fibrotic and degenerative diseases. Founded in 2017 by Paolo Michieli, the company focuses on growth factor mimetics that modulate regenerative pathways.

The master-stroke of AgomAb’s strategy was its recent $100 Million Series C funding round, which provides the runway necessary to move its lead candidates through late-stage clinical trials. By targeting the hepatocyte growth factor (HGF) and its receptor MET, AgomAb aims to achieve what was previously considered impossible: the reversal of established fibrosis in organs such as the liver and lungs.

2. AstriVax: A Paradigm Shift in Vaccine Deployment

AstriVax is a prime example of the high-impact spin-offs emerging from the KU Leuven Rega Institute. Under the leadership of CEO and co-founder Hanne Callewaert, the company is commercializing a versatile vaccine platform based on the yellow fever 17D (YF17D) vaccine.

This technology allows for the rapid engineering of vaccines against emerging infectious diseases and therapeutic targets in oncology. Having secured €30 Million in seed funding, a record for the region, AstriVax is advancing toward clinical Proof of Concept in 2024, with a scientific advisory board that includes global luminaries like Peter Piot.

3. Vertical Compute: The Infrastructure for On-Device Medical AI

Founded in 2024 as an imec spin-off, Vertical Compute addresses the fundamental physical limitation of modern computing: the memory bottleneck. Led by CEO Sylvain Dubois and CTO Sebastien Couet, the company has raised a total of €57 Million in seed funding to develop a 3D memory architecture. By stacking memory directly on top of logic, the platform achieves 100x improvement in the execution of Large Language Models (LLMs) and reduces energy consumption by 80%.

While a deep-tech company, the implications for MedTech are profound, enabling real-time, high-security processing of genomic data and physiological signals directly on portable medical devices without relying on vulnerable cloud infrastructure.

Vertical Compute Funding Trajectory	Seed Phase 1 (Jan 2025)	Seed Extension (Mar 2026)
Amount Raised	€20 Million	€37 Million
Total Funding	€20 Million	€57 Million
Lead Investor	imec.xpand	Quantonation
Strategic Support	Eurazeo, XAnge	PMV, Wallonie Entreprendre

4. Axithra: Photonics-on-Chip for Point-of-Care Monitoring

Axithra, a joint spin-off of imec and Ghent University, is revolutionising therapeutic drug monitoring (TDM). Led by CEO Leander Van Neste, the company utilises Raman-on-chip spectroscopy to measure drug concentrations in blood in real-time. Their primary application focuses on lactam antibiotics in intensive care units (ICUs). In critical care settings, the variation in patient metabolism is extreme; Axithra’s technology allows clinicians to adjust dosages every few minutes rather than waiting hours for a central lab report, directly impacting survival rates and preventing antibiotic resistance.

5. Novadip Biosciences: Regenerative Orthopedics from Stem Cells

Novadip Biosciences, based in the BioPark Charleroi, represents the pinnacle of Walloon excellence in ATMPs. Founded by Denis Dufrane, the company utilises an adipose-derived stem cell platform to create 3D tissue implants for bone reconstruction.

Their flagship product aims to heal complex bone defects that are currently untreatable. Having secured €22 Million in Series B funding, Novadip is entering late-stage clinical trials, positioning itself to capture a significant share of a potential €13.5 Billion market.

6. Minze Health: The Digitalisation of Urology and Pelvic Health

Minze Health has established itself as a leader in home-based urological diagnostics and digital therapeutics. Under the leadership of newly appointed CEO Thomas Moore—a veteran of the US MedTech market, Minze is scaling its platform for Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB).

Their products, which include automated bladder diaries and home-based uroflowmetry, enable continuous monitoring outside the clinic, improving both diagnostic accuracy and patient compliance. The company is currently preparing for a Series B fundraising round to support its US commercial expansion.

7. Mona Health: Retinal Analysis as a Diagnostic Window`````

Mona Health, founded by Olivier Ménage, utilises artificial intelligence to analyse retinal images for the early detection of glaucoma and other systemic conditions. Based in Mol, the company operates on the principle that the retina is a non-invasive window into the body’s vascular and neurological health.

By providing automated screening tools to optometrists and primary care physicians, Mona Health addresses the global shortage of ophthalmologists and facilitates early intervention for vision-threatening diseases.

8. Skinetix: Biomechanical Intelligence via Smart Sportswear

Skinetix is an imec and VUB spin-off that has successfully integrated electromyogram (EMG) sensors directly into textile fibers. Led by Joris De Winter and Kevin Langlois, the company provides real-time, field-based measurement of muscle activity. While the initial market focus is on professional sports organizations like international soccer clubs, the long-term MedTech value lies in post-injury recovery and neuro-rehabilitation.

By linking sensor data with personalised AI biomechanical models, Skinetix provides clinicians with quantitative data on muscle fatigue and movement quality that was previously only available in specialised gait labs.

9. Specifix: Automating the Preoperative Surgical Workflow

Specifix, an Antwerp-based healthtech startup, focuses on the high-precision requirements of orthopaedic surgery. Founded by Dr. Alejandra Ortega, Dr. Soha Mahdi, and Prof. Dr. Matthias Vanhees, the company provides automated 3D planning software for wrist fracture fixation.

The platform allows surgeons to upload CT scans and receive a fully automated preoperative plan, identifying the optimal personalised implants to stabilise the fracture. This reduction in operative time and increase in placement precision leads to faster patient recovery and fewer surgical complications.

10. FiriX Therapeutics: Inhibiting Ferroptosis in Organ Survival

FiriX Therapeutics is a 2025 spin-off from the University of Antwerp focusing on ischemia-reperfusion injury (IRI). Their lead candidate, FXT-001, is a first-in-class ferroptosis inhibitor designed to treat tissue damage that occurs when blood supply returns to oxygen-deprived organs.

This mechanism is critical in organ transplantation and the treatment of myocardial infarctions. FiriX has already demonstrated that FXT-001 is "organ-saving" in pig and human ex vivo transplant settings, representing a major advancement in transplant medicine.

11. Sightera Biosciences: Generative Drug Design via Tumoroid Screening

Sightera Biosciences utilises AI to revolutionise oncological drug discovery. Led by Hendrik Vercammen and Maxim Le Compte, the company integrates robotic high-throughput screening with generative AI to identify drug-response patterns in patient-derived "tumoroids".

This approach ensures that drug development is patient-relevant from the earliest stages, significantly increasing the probability of clinical success and reducing the multi-billion-dollar cost of drug failure.

12. Stimalia: Bioelectronic Implants for PTSD

Stimalia addresses the global crisis in mental health through neuromodulation. The company is developing a miniaturised, injectable bioelectronic implant that provides drug-free therapy for Post-Traumatic Stress Disorder (PTSD) via continuous nerve stimulation.

Led by a team of veterans from the neuro-modulation industry, including Olivier Ménage and Pascal Doguet, Stimalia’s device represents the transition of psychiatry from purely chemical interventions to precise electronic modulation of the nervous system.

13. Precirix: Nanobody-Based Radiopharmaceuticals

Precirix is a prominent player in the targeted radiation therapy sector, developing radiopharmaceuticals based on single-domain antibodies (nanobodies). These molecules are designed to deliver radioisotopes directly to tumor cells with high specificity, sparing healthy tissue.

Operating within the robust nuclear medicine ecosystem of Wallonia, Precirix leverages the region’s specialised logistics and isotope production to advance its clinical pipeline for several solid tumour indications.

14. Univercells: The Democratisation of Bioprocessing

Univercells is redefining the cost structure of vaccine and biologic production. Founded by Hugues Bultot and Jose Castillo, the company develops modular manufacturing platforms that allow for high-throughput production in a small footprint. This technology is critical for the "Health and Biotech Valley" initiative, as it enables the regional production of gene and cell therapies at a fraction of the cost of traditional cleanroom facilities.

15. Bioxodes: Redefining Haemorrhagic Stroke Treatment

Bioxodes is a Walloon drug development firm focusing on Ir-CPI, a first-in-class drug designed to prevent thrombosis and neuro-inflammation in patients suffering from haemorrhagic stroke. Unlike existing treatments that increase the risk of re-bleeding, Bioxodes’ molecule offers a safer profile.

The company is currently moving toward a pivotal Phase 2b trial, with a strategic goal of gaining market approval by 2030, addressing a massive unmet need in neurological emergency care.

16. ABSCINT: Next-Generation Molecular Imaging

ABSCINT is a molecular imaging company with two lead programs in cardiovascular disease and oncology. Their technology utilises nano-bodies for the imaging of vulnerable atherosclerotic plaques and tumour-specific antigens.

By providing clinicians with a more precise view of biological activity at the molecular level, ABSCINT enables personalised treatment adjustments that are not possible with traditional anatomical imaging like CT or MRI. The company aims to launch its first diagnostics in the EU and North America by 2028.

17. iTeos Therapeutics: Precision Cancer Immunotherapy

iTeos Therapeutics, a BioWin member, has transitioned from a promising startup to a clinical leader in cancer immunotherapy. The company recently released encouraging clinical data regarding its lung cancer treatment, which focuses on modulating the immune microenvironment of tumors. Their success reinforces Belgium’s reputation as a centre for high-value oncology research and provides a model for other startups aiming for IPO or major acquisition.

18. Thameus (Baby Detect): Genomic Preventive Medicine

Thameus is the spin-off responsible for the "Baby Detect" project, which has pioneered genomic newborn screening in Liège. While traditional screening focuses on a handful of diseases, Baby Detect uses targeted next-generation sequencing (NGS) to screen for over 160 treatable conditions from a single heel-prick sample. This project exemplifies the shift toward "predictive medicine," where intervention begins before symptoms appear, fundamentally altering the life-trajectory of children with rare genetic disorders.

19. Sequana Medical: Active Fluid Management in Chronic Disease

Sequana Medical, based in Ghent, has developed the alfapump®, a fully implantable, wirelessly charged pump system.The device is designed to manage fluid balance in patients with liver cirrhosis and congestive heart failure by automatically moving excess fluid from the abdomen to the bladder for natural elimination.

With over $52 Million in funding, Sequana is a leader in the medical engineering space, providing a significant quality-of-life improvement for patients who would otherwise require frequent, painful drainage procedures.

20. Brailsports: The AI Engine for Physiological Optimisation

Brailsports is a joint spin-off from imec, the University of Antwerp, and Ghent University. Led by CEO Erika Lutin, the company has developed an AI platform that accurately estimates an individual’s fitness and fatigue by analyzing cardiac and power data.

While initially focused on professional cycling teams, the platform’s core technology has broad medical applications in the prevention of overtraining syndrome and the monitoring of cardiac rehabilitation patients. Brailsports represents the vanguard of "digital coaching," where medical-grade insights are used to optimise human performance and prevent injury.

Cross-Sectoral Analysis and Market Dynamics

The Belgian HealthTech sector is characterised by an exceptionally high density of R&D and clinical development actors. This density creates a "cluster effect" where information and talent circulate rapidly. For example, the merger of MEDVIA and FlandersBio was driven by the recognition that biotech and medtech are no longer distinct silos.

Modern therapies, such as the ATMPs developed by Novadip, require specialised medical devices for delivery, while digital platforms like Awell Health are needed to manage the complex care pathways associated with these advanced treatments.

Core Pillars of Belgian HealthTech Specialisation	Representative Leaders	Strategic Hubs
Advanced Therapies (ATMP)	Novadip, AgomAb, Univercells	BioPark Charleroi
Nuclear Medicine	Precirix, ABSCINT, Trasis	Liège/LégiaPark
AI & Digital Diagnostics	Mona Health, Minze, Baby Detect	imec (Leuven), Antwerp
Precision MedTech	Axithra, Specifix, Sequana	Ghent/Leuven

The Role of Venture Capital and Public Support

Public-private partnerships are the lifeblood of the Belgian ecosystem. The Flemish investment company PMV and the Walloon equivalent Wallonie Entreprendre (WE) act as anchor investors, providing the stability necessary to attract international venture capital firms like V-Bio Ventures, Kurma Partners, and Earlybird Health.

In 2024, BioWin members secured €12.5 Million in combined funding, while larger scale-ups like AgomAb have demonstrated the ability to attract $100 Million rounds from global investors. This capital is supported by government subsidies from VLAIO (Flanders) and the SPW (Wallonia), which often provide non-dilutive funding for early-stage R&D.

Future Outlook: Challenges in Scaling and Internationalisation

As Belgium moves toward 2030, the primary challenge remains the transition from "frontier research" to "meaningful industrial transformation". While the country excels at launching startups, scaling them into global market leaders requires access to even larger capital pools and a deep understanding of the US healthcare market. The "Health and Biotech Valley" initiative is designed to address this by fostering international alliances and providing specialised training for founders.

Furthermore, the integration of innovation into the Belgian hospital system remains a hurdle. The "Health on Stage" symposium in 2026 addressed this by inviting hospitals to present their "real-world challenges" to the startup community, flipping the traditional sales-pitch model.

Projects like SIM BLOOD, a serious game for transfusion training developed by Cliniques de l'Europe and PLAY IT, won Innovation Awards for demonstrating tangible hospital impact, suggesting that the future of Belgian HealthTech lies in co-creation between engineers and clinicians.

Conclusion: The Convergence of Biology and Bits

The Belgian HealthTech and MedTech ecosystem has entered a period of unprecedented convergence. The 20 leaders identified in this report are not merely developing better medical products; they are redefining the mechanisms of diagnosis, therapy and patient management through the integration of artificial intelligence, photonics, and regenerative biology.

Supported by world-class institutions like VIB, imec and a regional strategy that emphasises specialised clusters and international proximity, Belgium is well-positioned to remain a global leader in health innovation for the foreseeable future. The continued success of these firms will depend on their ability to maintain technical excellence while navigating the commercial complexities of a globalized healthcare economy.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech